measles + mumps + rubella + pneumococcal vaccine

This combination vaccine regimen refers to a specific immunization protocol evaluated by the National Institute of Allergy and Infectious Diseases (NIAID) in clinical trials such as PACTG 1024. The regimen consists of the live-attenuated Measles, Mumps, and Rubella (MMR) vaccine administered alongside pneumococcal vaccines, specifically the 7-valent pneumococcal conjugate vaccine (PCV7) and the 23-valent pneumococcal polysaccharide vaccine (PPV23). The primary objective of this combination in the NIAID context was to evaluate the safety and immunogenicity of routine pediatric vaccines in HIV-infected children who are stable on Highly Active Antiretroviral Therapy (HAART). By combining these vaccines, researchers aimed to determine if the immune systems of HIV-infected children could mount and maintain protective antibody responses against these common childhood pathogens, particularly Streptococcus pneumoniae, which is a major cause of morbidity in this population.

Brand names

M-M-R IIPrevnarPneumovax 23Pneumovax23Pneumovax-23

Other names

MMR-PCV7-PPV23 combinationMMR-PCV-7-PPV23 combinationMMR-PCV 7-PPV23 combinationMeasles-Mumps-Rubella Vaccine (Live) + Pneumococcal Conjugate Vaccine (Heptavalent) + Pneumococcal Vaccine Polyvalent (23-valent)